ADAP

Adaptimmune Therapeutics

0.0996 USD
-0.0053
5.05%
At close Jul 30, 4:00 PM EDT
After hours
0.0979
-0.0017
1.71%
1 day
-5.05%
5 days
-66.79%
1 month
-58.45%
3 months
-64.00%
6 months
-83.65%
Year to date
-84.03%
1 year
-92.34%
5 years
-98.89%
10 years
-99.34%
 

About: Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Employees: 506

0
Funds holding %
of 7,323 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

633% more call options, than puts

Call options by funds: $22K | Put options by funds: $3K

6% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 16

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

0.58% less ownership

Funds ownership: 8.1% [Q4 2024] → 7.52% (-0.58%) [Q1 2025]

15% less funds holding

Funds holding: 79 [Q4 2024] → 67 (-12) [Q1 2025]

53% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 19

66% less capital invested

Capital invested by funds: $67M [Q4 2024] → $22.9M (-$44.2M) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$0.46
362%
upside
Avg. target
$0.65
556%
upside
High target
$1
904%
upside

3 analyst ratings

positive
0%
neutral
67%
negative
33%
Mizuho
Graig Suvannavejh
402%upside
$0.50
Neutral
Downgraded
26 Jun 2025
Barclays
Peter Lawson
362%upside
$0.46
Underweight
Maintained
14 May 2025
Wells Fargo
Yanan Zhu
904%upside
$1
Equal-Weight
Maintained
14 May 2025

Financial journalist opinion

Neutral
Newsfile Corp
2 days ago
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with Galapagos Purchase price is $55m in cash to be paid upon consummation of the sale with up to $30m in potential future payments upon achievement of certain milestones Adaptimmune will retain rights to its preclinical assets including PRAME, CD70, and its allogeneic program Adaptimmune will restructure to support the transition of these therapies to US WorldMeds and to maximize value from its remaining assets Adaptimmune's Board of Directors determined this transaction is in the best interest of all stakeholders following a comprehensive review of all strategic alternatives Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - July 28, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced its entry into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds. Consummation of the sale is expected to occur before the end of the week.
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
Neutral
Seeking Alpha
2 months ago
Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Cintia Piccina - Chief Commercial Officer Dennis Williams - SVP, Late Stage Development Gavin Wood - CFO John Lunger - VP, Manufacturing Conference Call Participants Marc Frahm - TD Cowen Jonathan Chang - SVB Leerink Arthur He - H.C. Wainwright Graig Suvannavejh - Mizuho Yanan Zhu - Wells Fargo Securities Operator Hello and welcome to Adaptimmune's First Quarter 2025 Business Update Conference Call.
Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript
Neutral
Newsfile Corp
2 months ago
Adaptimmune Reports Q1 Financial Results and Provides Business Update
TECELRA ® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of $35-$45 million Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026 Adaptimmune had Total Liquidity 1 of $60 million as of March 31, 2025; call at 8 a.m. EDT today Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reported financial results and provided a business update for the first quarter ended March 31, 2025.
Adaptimmune Reports Q1 Financial Results and Provides Business Update
Neutral
Newsfile Corp
2 months ago
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m.
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Neutral
Seeking Alpha
4 months ago
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Cintia Piccina - Chief Commercial Officer Gavin Wood - CFO Dennis Williams - SVP, Late Stage Development John Lunger - VP, Manufacturing and Supply Chain Conference Call Participants Jonathan Chang - Leerink Partners Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho George Farmer - Scotiabank Arthur He - H.C. Wainwright Michael Kim - Zacks Small Cap Research Peter Lawson - Barclays Operator Hello, and welcome to the Adaptimmune's Q4 and Full Year 2024 Business Update Conference Call.
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
Neutral
Newsfile Corp
4 months ago
Adaptimmune Provides Q4 and Full Year 2024 Business Update
TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026 Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programs At the end of 2024, Adaptimmune had Total Liquidity 1 of $152 million Evaluating all strategic options to maximize shareholder value Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today provided a Q4 and Full Year 2024 business update. Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "2025 is the year of commercial execution for Tecelra, as we begin to generate value from our promising sarcoma franchise.
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Neutral
Newsfile Corp
4 months ago
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m.
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Neutral
Newsfile Corp
5 months ago
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February. Guggenheim Securities SMID Cap Biotech Conference, New York, NY Fireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m.
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Neutral
Newsfile Corp
6 months ago
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets Adaptimmune Allo-T program to be featured at the Biotech ShowCase (TM) and the Wuxi Global Forum 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that letetresgene autoleucel (lete-cel), has been granted breakthrough therapy designation by the U.S. FDA for the treatment of patients with unresectable or metastatic myxoid/round cell liposarcoma (MRCLS) who have received prior anthracycline-based chemotherapy, are positive for HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06, and whose tumor expresses the NY-ESO-1 antigen.
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Neutral
Newsfile Corp
7 months ago
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down from the Company May 31, 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 19, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that two of its executive leadership team members based in the UK will leave the Company next year.
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Charts implemented using Lightweight Charts™